Abbott rolled out its first over-the-counter glucose sensor in the U.S. on Thursday, just over one week after Dexcom began selling its competing product. The device, called Lingo, is intended to be ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

Headlines,DexCom is positioned for long-term growth as diabetes cases are expected to rise, driving demand for continuous ...

As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

Just 15% of current baby boomer homeowners expect to sell their homes in the next five years, while more than half (54%) never plan to sell, according to new research from Clever Real Estate, a St.

The announcement comes just after Dexcom, another diabetes company, released its own consumer-friendly sensor. Here's what to ...

THE LAWSUIT: A class action securities lawsuit was filed against DexCom, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 8, ...

Ithaka US Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the second quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company engages in the ...

New York, New York--(Newsfile Corp. - September 3, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, ...